Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

149.99 +0.38 (+0.25%)
Streaming Delayed Price Updated: 12:59 PM EDT, Sep 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,222,214
Open 150.67
Bid (Size) 149.94 (200)
Ask (Size) 149.98 (200)
Prev. Close 149.61
Today's Range 148.41 - 150.80
52wk Range 108.46 - 157.29
Shares Outstanding 1,253,809,440
Dividend Yield 2.19%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ ↗
Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns. 
Via The Motley Fool
Topics ETFs
News headline image
FDA Approves Gilead's New Single Tablet HIV Regimen ↗
The FDA approved Gilead Sciences' Bixlenvo, a new once-daily single tablet regimen for virologically suppressed adults treating HIV. 
Via Benzinga

Performance

YTD
+23.3%
+23.3%
1 Month
+14.4%
+14.4%
3 Month
+16.3%
+16.3%
6 Month
+1.2%
+1.2%
1 Year
+33.1%
+33.1%

More News

Read More
News headline image
3 Unpopular Stocks with Open Questions
Via StockStory
News headline image
Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals? ↗
Via The Motley Fool
Topics ETFs
What's going on in today's after hours session: S&P500 movers ↗
Via Chartmill
News headline image
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting ↗
Via The Motley Fool
News headline image
3 Dividend Stocks to Hold for the Next 10 Years ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
3 Unprofitable Stocks with Questionable Fundamentals
Via StockStory
News headline image
$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket? ↗
Via The Motley Fool
Topics ETFs
News headline image
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy? ↗
Via The Motley Fool
Topics ETFs
News headline image
Worried About a Market Crash? These 3 Stocks Beat the S&P 500 in 2008 and 2022 ↗
Via The Motley Fool
Topics Economy Stocks
News headline image
Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? ↗
Via The Motley Fool
Topics ETFs
News headline image
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited. ↗
Via The Motley Fool
News headline image
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?
Via StockStory
Topics Stocks
Global Drugmakers Earmark Billions to Ramp Up Their US Footprint
Via Investor Brand Network
Topics World Trade
News headline image
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
KLA, Snowflake, Airbnb And A Health Care Stock On CNBC’s ‘Final Trades’ ↗
Via Benzinga
News headline image
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today ↗
Via Benzinga
News headline image
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
Via StockStory
Topics Earnings
News headline image
Compugen (CGEN) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
3 Healthcare Stocks with Open Questions
Via StockStory

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 149.99
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 09/03/26 12:59 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 188.06B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 188B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.